Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Italy Fines Apple €98.6 Million Over App Store Dominance 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
NEW YORK, Jan. 30, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PixarBio Corporation (OTCMKTS:PXRB) securities (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/pixarbio-corporation. There is no cost or obligation to you.
According to the complaint, PixarBio made false and/or misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) certain assertions in press releases, third party promotional materials, and PixarBio’s Form S-1 lacked accuracy; and (3) as a result, the Company’s public statements were materially false and misleading.
If you suffered a loss in PixarBio you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/pixarbio-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
